BACKGROUND: @entity6542 ( @entity6542 ) still remains the only causal treatment for IgE mediated @entity1576 ( @entity2490 / @entity565 ) In addition to the observed clinical decrease in symptoms, @entity6542 can provide a long-lasting and preventive effect. In particular it can modify the progression from @entity2490 to @entity565 . METHODS: The study was observational, open, non randomized, controlled, prospective and performed in a real-life setting. @entity1 with pure mite-induced @entity2023 were followed-up, receiving adjuvanted SLIT (aSLIT), standard SLIT (sSLIT) or drug treatment alone, according to their preference starting between 2008 and 2009. The possible onset of @entity565 , changes in pulmonary function and @entity6587 ( @entity6587 ) were assessed over a 5-year horizon. Also the onset of new sensitizations and @entity1109 ( @entity1109 ) were evaluated. RESULTS: One hundred forty two @entity1 fulfilling the inclusion criteria were assessed at baseline, and 124 had the 5-year evaluation (age range 8-57, 69 male). After 5  years of treatment, new sensitizations appeared differentially among treatments with 58.1% of new sensitizations in the drug treatment group, 13.2% in the sSLIT @entity1 , and 8.1% in the aSLIT @entity1 . At the end of 5  years, @entity1109 significantly changed (P   <   0.001) in all groups, with a negative trend for controls, as compared to the SLIT treatments. The @entity1109 decreased in both SLIT groups at 5  years, with no change in @entity1 on drug treatment alone. The use of @entity3045 (absent at baseline), showed an overall increase only in the group receiving drugs alone with a significant difference at 5  years (P   <   0.001). Considering the @entity27127 challenge, there was a difference among treatments (P   <   0.001) in PD20 after 5  years: the control group had a lower PD20 at 5  years. No significant difference in PD20 was detected between sSLIT and aSLIT. The FEV1 significantly decreased in controls, with no change in the sSLIT group and a significant increase in aSLIT as compared to sSLIT. DISCUSSION: Despite the limitations inherent to a real-life setting study (absence of randomization and control, small sample size, lack of intermediate timepoint assessment) the results of this study evidenced that the investigated SLIT product, either adjuvanted or not, had a positive effect on the evolution of @entity1576 due to house dust mite. CONCLUSION: In the real life setting, considering a 5-year period, aSLIT and sSLIT reduced the onset of new sensistizations and maintained intact the pulmonary function, as compared to @entity1 receiving drug treatment alone.

Effect of adjuvanted and standard sublingual immunotherapy on respiratory function in pure XXXX due to house dust mite over a 5-year period.

@entity6542 :: ('MESH:C562465', 'Disease') :: ['AIT', 'Allergen-specific immunotherapy'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity2023 :: ('MESH:D006255', 'Disease') :: ['allergic rhinitis'] @entity27127 :: ('5367', 'Gene') :: ['MCh'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity3045 :: ('MESH:D000420', 'Chemical') :: ['salbutamol'] @entity1109 :: ('MESH:D012678', 'Disease') :: ['SMS', 'symptoms-medication score'] @entity2490 :: ('MESH:D012220', 'Disease') :: ['rhinitis'] @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory diseases', 'respiratory allergy'] @entity6587 :: ('MESH:D016535', 'Disease') :: ['bronchial hyperreactivity', 'BHR']
@entity2490 :: (MESH:D012220,Disease) :: ['rhinitis']
